Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Race Oncology Ltd. ( (AU:RAC) ) just unveiled an announcement.
Race Oncology director Daniel Tillett has increased his equity stake in the company by exercising 200,000 options at an exercise price of $1.25 per share, investing a total of $250,000. Following the transaction, Tillett now holds 18,821,009 fully paid ordinary shares, while his holding of options exercisable at $1.25 has decreased to 1,448,342, leaving his other option positions unchanged.
The move signals ongoing alignment between management and shareholders, as a key director commits additional capital to the business rather than selling down his derivative exposure. This adjustment in Tillett’s holdings modestly strengthens insider ownership, which investors often view as a vote of confidence in the company’s prospects and operational trajectory.
The most recent analyst rating on (AU:RAC) stock is a Buy with a A$3.00 price target. To see the full list of analyst forecasts on Race Oncology Ltd. stock, see the AU:RAC Stock Forecast page.
More about Race Oncology Ltd.
Race Oncology Ltd. is a biotechnology company focused on oncology, developing cancer therapeutics aimed at improving treatment options for patients. The company is listed on the ASX and its activities are closely tied to the clinical and commercial progression of its drug pipeline within the competitive cancer treatment market.
Average Trading Volume: 184,050
Technical Sentiment Signal: Buy
Current Market Cap: A$458.6M
See more insights into RAC stock on TipRanks’ Stock Analysis page.